Growth inhibition and apoptosis in human Philadelphia chromosome-positive lymphoblastic leukemia cell lines by treatment with the dual PPARalpha/gamma ligand TZD18

• Published in: Blood Vol. 107; no. 9; p. 3683
• Main Authors: Liu, Hongyu, Zang, Chuanbing, Fenner, Martin H, Liu, Dachuan, Possinger, Kurt, Koeffler, H Phillip, Elstner, Elena
• Format: Journal Article
• Language: English
• Published: United States 01.05.2006
• Subjects: Apoptosis - drug effects; Benzamides; Cell Cycle - drug effects; Cell Division - drug effects; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; Humans; Imatinib Mesylate; Intracellular Signaling Peptides and Proteins - metabolism; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology; Ligands; NF-kappa B - metabolism; Phenyl Ethers - administration & dosage; Phenyl Ethers - pharmacology; Piperazines - administration & dosage; PPAR alpha - agonists; PPAR alpha - genetics; PPAR gamma - agonists; PPAR gamma - genetics; Pyrimidines - administration & dosage; Thiazolidinediones - administration & dosage; Thiazolidinediones - pharmacology
• ISSN: 0006-4971

Treatment of adult Philadelphia chromosome-positive lymphocytic leukemia is rarely successful. We report here the effects of TZD18, a novel dual ligand specific for peroxisome proliferator-activated receptor alpha and gamma (PPARalpha/gamma) on Ph(+) lymphocytic leukemia cell lines BV173, SD1, and SupB-15. Exposure of these cells to TZD18 resulted in growth inhibition in a dose- and time-dependent manner that was associated with G(1) cell cycle arrest. This effect was much stronger than that mediated by the PPARgamma ligand pioglitazone (PGZ), which also belongs to the thiazolidinediones (TZD) class of ligands. However, it may not be mediated through PPARgamma or PPARalpha activation because antagonists of PPARgamma and PPARalpha cannot reverse it. Study of the key regulators of cell cycle progression by Western blot analysis showed that the expression of the cyclin-dependent kinase inhibitor (CDKI) p27(kip1), but not that of p21(cip1), was enhanced, whereas that of c-Myc, cyclin E, cyclin D2, and cyclin-dependent kinases 2 and 4 (CDK-2 and CDK-4) was decreased when these cells were treated with TZD18 (10 or 20 microM). Therefore, the up-regulation of p27(kip1) and the down-regulation of CDK-2 and CDK-4 may, at least in part, account for the G(1) cell cycle arrest. Furthermore, a remarkable induction of apoptosis was observed in the cells treated with this dual ligand. No obvious alteration of bcl-2 protein level occurred, but bax was up-regulated in these TZD18-treated cells. Activation of caspase 8 and caspase 9 by TZD18 was also observed. Importantly, NF-kappaB DNA-binding activity was markedly decreased by the TZD18 treatment. In addition, TZD18 enhanced the growth inhibitory effect of imatinib, a specific tyrosine kinase inhibitor therapeutically used in the treatment of Ph(+) leukemia. Overall, our findings strongly suggest that TZD18 may offer a new therapeutic approach to aid in the treatment of Ph(+) lymphocytic leukemia.